These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 3118798)

  • 1. In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.
    Bosso JA; Saxon BA; Matsen JM
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1403-5. PubMed ID: 3118798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
    Breen SKJ; Harper M; López-Causapé C; Rogers KE; Tait JR; Smallman TR; Lang Y; Lee WL; Zhou J; Zhang Y; Bulitta JB; Nation RL; Oliver A; Boyce JD; Landersdorfer CB
    Int J Antimicrob Agents; 2024 Jun; 63(6):107161. PubMed ID: 38561094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.
    Bosso JA; Saxon BA; Matsen JM
    Antimicrob Agents Chemother; 1990 Mar; 34(3):487-8. PubMed ID: 2110438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia.
    Chin NX; Neu HC
    Diagn Microbiol Infect Dis; 1989; 12(4):343-9. PubMed ID: 2512049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation.
    Schechter MS; Trueman D; Farquharson R; Higuchi K; Daines CL
    Ann Am Thorac Soc; 2015 Jul; 12(7):1030-8. PubMed ID: 26053185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of amiloride combined with tobramycin against Pseudomonas isolates from patients with cystic fibrosis.
    Cohn RC; Jacobs M; Aronoff SC
    Antimicrob Agents Chemother; 1988 Mar; 32(3):395-6. PubMed ID: 3364958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells.
    Yu Q; Griffin EF; Moreau-Marquis S; Schwartzman JD; Stanton BA; O'Toole GA
    J Antimicrob Chemother; 2012 Nov; 67(11):2673-81. PubMed ID: 22843834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Balke B; Hogardt M; Schmoldt S; Hoy L; Weissbrodt H; Häussler S
    Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):25-30. PubMed ID: 16402226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa.
    Weiss K; Lapointe JR
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2411-4. PubMed ID: 8585718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis.
    Nichols DP; Happoldt CL; Bratcher PE; Caceres SM; Chmiel JF; Malcolm KC; Saavedra MT; Saiman L; Taylor-Cousar JL; Nick JA
    J Cyst Fibros; 2017 May; 16(3):358-366. PubMed ID: 28025037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
    Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
    J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis.
    Nick JA; Moskowitz SM; Chmiel JF; Forssén AV; Kim SH; Saavedra MT; Saiman L; Taylor-Cousar JL; Nichols DP
    Ann Am Thorac Soc; 2014 Mar; 11(3):342-50. PubMed ID: 24476418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxalactam-tobramycin-resistant Pseudomonas aeruginosa isolates in patients with cystic fibrosis.
    Fitzpatrick SB; Rosenstein BJ
    Clin Pediatr (Phila); 1983 Sep; 22(9):628-30. PubMed ID: 6224623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis.
    Aronoff SC; Klinger JD
    Antimicrob Agents Chemother; 1984 Feb; 25(2):279-80. PubMed ID: 6561954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Hansen C; Skov M
    Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
    Traczewski MM; Brown SD
    Antimicrob Agents Chemother; 2006 Feb; 50(2):819-21. PubMed ID: 16436756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of rapidly developing resistance during treatment of cystic fibrosis patients with aztreonam.
    Allen JE; Bosso JA; Saxon BA; Matsen JM
    Diagn Microbiol Infect Dis; 1987 Sep; 8(1):51-5. PubMed ID: 3126018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between the in-vitro activity of new agents on Pseudomonas aeruginosa isolates from cystic fibrosis patients and other chronic infections.
    Gordts B; Vandenborre C; VanderAuwera P; Butzler JP
    J Antimicrob Chemother; 1984 Jul; 14(1):25-9. PubMed ID: 6434504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis.
    Bosso JA; Black PG
    Pediatr Infect Dis J; 1988 Mar; 7(3):171-6. PubMed ID: 3128767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.
    Pedersen SS; Pressler T; Jensen T; Rosdahl VT; Bentzon MW; Høiby N; Koch C
    J Antimicrob Chemother; 1987 Jan; 19(1):101-7. PubMed ID: 3104273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.